¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚvic3308 ¤™
-
¿Æ¼¼Á¢Òì ¤™
-
²úÆ·ÓëÓªÒµ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°ÒµÉú³¤ ¤™
¼ò
¤™
Ò»ÏîÓɱ±¾©´óѧÈËÃñÒ½ÔºÉöÄÚ¿ÆÍŶӿªÕ¹µÄÑо¿£¬£¬£¬£¬£¬£¬Õ¹ÏÖÁËÅàĪɳëĵÄÐļ¡±£»£»£»£»£»¤×÷ÓûúÖÆ[1]¡£¡£¡£¡£ ¡£¸ÃÑо¿µÄÍêÕûÄÚÈÝÒÑÓÚ½üÆÚ½ÒÏþÔÚ¡¶¹ú¼ÊÃâÒßÒ©Àíѧ¡·ÔÓÖ¾(International Immunopharmacology£¬£¬£¬£¬£¬£¬IF 4.7)¡£¡£¡£¡£ ¡£Ñо¿Ê¹ÓÃH9c2Ðļ¡Ï¸°ûÄ£×Ó£¬£¬£¬£¬£¬£¬Ö¤ÊµÎúÅàĪɳëÄÄܹ»Í¨¹ýÒÖÖÆCD131±í´ï¡¢×è¶ÏEPOR-CD131Òì¶þ¾ÛÌåµÄÐγɣ¬£¬£¬£¬£¬£¬½ø¶ø×è¶ÏJAK2/STAT3ͨ·µÄ¼¤»î£¬£¬£¬£¬£¬£¬´Ó¶øÓÐÓûº½âÁòËáßÅßá·Ó£¨IS£©ÓÕµ¼µÄÐļ¡Ï¸°û·Ê´ó[3]¡£¡£¡£¡£ ¡£
ÕâΪÅàĪɳëÄDZÔÚµÄÇå¾²ÐÔÓÅÊÆ£¨ÀýÈçïÔÌÐÄѪ¹Ü²»Á¼ÊÂÎñ£©¼°ÆäÆæÒìµÄÐÄÔà±£»£»£»£»£»¤ÌØÕ÷£¬£¬£¬£¬£¬£¬ÌṩÁËÓÐÁ¦µÄ»úÖÆÒÀ¾Ý¡£¡£¡£¡£ ¡£
¼ÈÍù½ÒÏþµÄIIIÆÚÁÙ´²Ñо¿Ð§¹ûÏÔʾ£¬£¬£¬£¬£¬£¬ÎÞÂÛÊÇ͸ÎöÈËȺÕվɷÇ͸ÎöÈËȺ£¬£¬£¬£¬£¬£¬ÅàĪɳëÄ×éµÄ¸´ºÏÇå¾²ÐÔÊÂÎñ£¨°üÀ¨È«ÒòéæÃü¡¢×äÖкÍÐļ¡¹£ËÀ£©ºÍÆäËûÐÄѪ¹ÜÊÂÎñ£¨°üÀ¨ÐèҪסԺÖÎÁƵIJ»Îȶ¨ÐĽÊÍ´ºÍÐèҪסԺÖÎÁƵÄÐÄÁ¦Ë¥½ß£©±¬·¢ÂʾùµÍÓÚ¶ÌЧ´ÙºìËØ×é[4,5]¡£¡£¡£¡£ ¡£ASN 2024Ðû²¼µÄÒ»ÏîÕë¶Ô͸ÎöÈËȺµÄIIIÆÚÑо¿ÊºóÆÊÎö»¹ÏÔʾ£¬£¬£¬£¬£¬£¬ÅàĪɳëÄ×éµÄ¸ßѪѹ¡¢¸Î¶¾ÐԺ͸߼ØѪ֢±¬·¢ÂÊÒ²¾ùµÍÓÚ¶ÌЧ´ÙºìËØ×é[6]¡£¡£¡£¡£ ¡£
±¾´ÎASN´ó»áÐû²¼µÄÁíÒ»Ïî»ùÓÚÁ½¸öIIIÆÚÁÙ´²Ñо¿(NCT03902691£¬£¬£¬£¬£¬£¬NCT03903809)µÄʺóÆÊÎö£¬£¬£¬£¬£¬£¬½øÒ»²½ÆÀ¹ÀÁËÅàĪɳëĵÄÁÆЧºÍÐÄѪ¹ÜÇå¾²ÐÔ¡£¡£¡£¡£ ¡£ÎÞÂÛÔÚ͸ÎöÕվɷÇ͸ÎöÈËȺÖУ¬£¬£¬£¬£¬£¬ÅàĪɳëľùÄÜʹ¾ø´ó´ó¶¼£¨¡Ý87%£©µÄ»¼ÕßʵÏÖHb¡Ý10g/dL£¬£¬£¬£¬£¬£¬´ï±êÂʾù¸ßÓÚ¶ÌЧ´ÙºìËرÈÕÕ×飬£¬£¬£¬£¬£¬ÇÒÖ÷ÒªÐÄѪ¹Ü²»Á¼ÊÂÎñ(5P-MACE£º°üÀ¨ÐÄѪ¹ÜéæÃü¡¢Ðļ¡¹£ËÀ¡¢×äÖС¢²»ÎȹÌÐÔÐĽÊÍ´¼°ÐèסԺµÄÐÄÁ¦Ë¥½ß)ºÍÀ©Õ¹ÐÄѪ¹ÜÊÂÎñµÄ±¬·¢ÂʾùÒ»Ö¸üµÍ¡£¡£¡£¡£ ¡£ÆäÖУ¬£¬£¬£¬£¬£¬Í¸Îö»¼ÕßÖУ¬£¬£¬£¬£¬£¬ÅàĪɳëÄÏà±È±ÈÕÕ×éµÄ5P-MACEΣº¦Ï½µ65%(HR 0.35,95%CI 0.11-1.10)£»£»£»£»£»·Ç͸Îö»¼ÕßÖÐÔòÏà±È±ÈÕÕ×éϽµ86%(HR 0.14,95%CI 0.02-1.28)¡£¡£¡£¡£ ¡£ÌáÐÑÅàĪɳëÄÏà±È¶ÌЧ´ÙºìËؾßÓнµµÍÐÄѪ¹ÜÊÂÎñΣº¦µÄDZÔÚ»ñÒæ[2]¡£¡£¡£¡£ ¡£
ѪÐé»áÔöÌíCKD»¼ÕßÐÄѪ¹ÜÊÂÎñ¼°éæÃüµÄΣº¦[7]£¬£¬£¬£¬£¬£¬Òò´Ë£¬£¬£¬£¬£¬£¬Æ𾢿ØÖÆѪÐéÊÇCKDÖÎÀíµÄÖ÷Òª×é³É²¿·Ö¡£¡£¡£¡£ ¡£¹Å°åµÄ¶ÌЧ´ÙºìËØÔÚÎÒ¹úÉöÐÔѪÐéÁìÓòÒÑÆÕ±éʹÓöàÄ꣬£¬£¬£¬£¬£¬µ«ÓÐÑо¿ÏÔʾÆä»áÔöÌíÐÄѪ¹ÜÊÂÎñÉõÖÁéæÃüΣº¦[8]¡£¡£¡£¡£ ¡£Òò´Ë£¬£¬£¬£¬£¬£¬ÉöÐÔѪÐéµÄÖÎÁÆÒ©ÎïÔÚ×·ÇóHb´ï±êµÄͬʱ»¹Ó¦¼æ¹ËÇå¾²ÐÔ¡£¡£¡£¡£ ¡£
ÅàĪɳëÄÏÖÔÚÒÑÔ½À´Ô½ÆÕ±éµØÓÃÓÚCKDÏà¹ØѪÐéµÄÖÎÁÆ£¬£¬£¬£¬£¬£¬²¢Ïà¼Ì»ñµÃ¡¶³¤Ð§ºìϸ°ûÌìÉú´Ì¼¤¼ÁÖÎÁÆÉöÐÔѪÐéÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©¡·[9]¡¢¡¶Ö¸µ¼ÉöÐÔѪÐ黼Õß×ÔÎÒÖÎÀíµÄÖйúר¼Ò¹²Ê¶(2024 °æ)¡·[10]ÒÔ¼°¡¶ÑÓ»ºÂýÐÔÉöÔಡϣÍûÁÙ´²ÖÎÀíÖ¸ÄÏ£¨2025Äê°æ£©¡·[11]µÄÍƼöÈÏ¿É¡£¡£¡£¡£ ¡£
±¾´ÎASN´ó»áÒÔ¼°¼ÈÍù½ÒÏþµÄÏà¹ØÑо¿¾ù֤ʵÁËÅàĪɳëľßÓÐÈ·ÇеĿ¹ÑªÐéÁÆЧºÍÓÅÒìµÄÐÄѪ¹ÜÇå¾²ÐÔ£¬£¬£¬£¬£¬£¬Õ⽫ÓÐÖúÓÚ¸ÄÉÆÉöÐÔѪÐéµÄºã¾ÃÖÎÀí£¬£¬£¬£¬£¬£¬ÊµÏÖѪÐéµÄÎȹÌÒ»Á¬¿ØÖÆ£¬£¬£¬£¬£¬£¬¸ÄÉÆCKD»¼ÕßµÄÉúÑÄÔ¤ºó¡£¡£¡£¡£ ¡£
²Î¿¼ÎÄÏ×£º
1.Zhang, Xinyu,et al.Pegmolesatide Ameliorates Indoxyl Sulfate-Induced Cardiomyocyte Hypertrophy Through Modulating the EPOR-CD131-Dependent JAK2/STAT3 Signaling Pathway. ASN 2025. Abstract: TH-PO0288
2.Chen Jianghua, et al. Efficacy and Cardiovascular Safety of Pegmolesatide in Renal Anemia: Post Hoc Analysis of Two Phase 3 Trials. ASN 2025. Abstract: FR-PO0199
3.Zhang X, Li S, Lin T,et al.Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2/STAT3 signaling pathway.Int Immunopharmacol. 2025 Oct 14;167:115643.
4.Ping Zhang, et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. EClinicalMedicine. 2023 Oct 28; 65:102273
5.Xie J, et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD. Kidney Int Rep. 2024 Dec 6;10(3):720-729.
6.Chen Jianghua,et al.Pegmolesatide for the Treatment of Anemia in Patients with CKD Undergoing Dialysis: Insights from a Randomized Active-Controlled Phase 3 Study. ASN 2024. ABSTRACT: TH-PO888
7.ÖйúÉöÐÔѪÐéÕïÖÎÁÙ´²Êµ¼ùÖ¸ÄÏ. ÖлªÒ½Ñ§ÔÓÖ¾,2021,101(20):1463-1502.
8.Palmer SC, et al.Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010 Jul 6;153(1):23-33.
9.³¤Ð§ºìϸ°ûÌìÉú´Ì¼¤¼ÁÖÎÁÆÉöÐÔѪÐéÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©. ÖлªÉöÔಡÔÓÖ¾,2024,40(2):146-157.
10.Ö¸µ¼ÉöÐÔѪÐ黼Õß×ÔÎÒÖÎÀíµÄÖйúר¼Ò¹²Ê¶(2024 °æ). ÖйúѪҺ¾»»¯.2025,24(1):1-12
11.ÑÓ»ºÂýÐÔÉöÔಡϣÍûÁÙ´²ÖÎÀíÖ¸ÄÏ£¨2025Äê°æ£©. ÖлªÉöÔಡÔÓÖ¾,2025,41(6):455-488.
¹ØÓÚº²ÉÖÆÒ©
ÃâÔðÉùÃ÷
Ç°Õ°ÐÔ˵Ã÷
